Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?

Novo Nordisk is one of the leading developers of weight-loss drugs. It just shared some great early-stage clinical trial data from one of its programs.

1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant

Novo Nordisk, the Danish drug maker whose fortunes have soared on the popularity of its GLP-1 agonist drugs, scored a long-sought label expansion for its weight-loss drug Wegovy on Friday, with FDA approving it to reduce the risk of major cardiovascular events in adults who are obese or overweight and have established cardiovascular disease.

Wegovy is no longer just a weight-loss drug

NVIDIA

Building a stock investment portfolio isn't easy. One moment, you are tempted to wait for a dip, and another, you want to give in to the temptation of buying a stock at a premium with the hopes that it will generate strong returns.

On the Dip: 3 Stocks to Snatch Up Whenever the Market Stumbles

Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

Amgen

Pfizer

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis.

Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks

Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-class dual GLP-1 and amylin agonist that shrank patients' body weight by a placebo-adjusted 12% after 12 weeks of treatment.

Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?

Johnson & Johnson

Eli Lilly

Investors' eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15 trillion.

The Top 3 Pharma Stocks to Buy in March2024

Structure Therapeutics Inc

Viking Therapeutics

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, federal regulators said Friday.

The FDA approved Wegovy for reducing heart attack and stroke risk in overweight patients

The move confirms that the new class of obesity medications are useful for improving health, not just losing weight.

Weight-loss drug Wegovy approved by FDA to cut heart attack, stroke risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday.

FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks

Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage

Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.

Novo Nordisk CEO says experimental weight loss pill could become a best in class drug

Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.

Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.

Novo Nordisk hopes to launch experimental obesity drug this decade

Novo Nordisk's CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segments.

Novo Nordisk CEO says innovation in obesity may justify higher price in some segments

The stock move comes as Novo Nordisk, maker of obesity drug Wegovy, overtook Tesla's market value Thursday.

Tesla Stock Is Rising. Novo Nordisk Overtakes the EV Maker's Valuation.

Novo Nordisk's CEO on Friday said compounded semaglutide in the United States is a serious health issue.

Compounded semaglutide poses serious U.S. health issue, Novo Nordisk CEO says

Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.

Novo Nordisk market cap surpasses Tesla on new obesity pill trial data

Novo Nordisk will prioritise acquisitions that can complement its pipeline of obesity and diabetes drugs rather than buying supply chain companies, the Danish group's head of business development told Reuters on Friday.

Novo Nordisk seeks acquisitions to boost obesity, diabetes pipeline

Novo Nordisk hopes to launch experimental obesity drug "within this decade"

Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polished performance' at its capital markets day earlier this week, but added "we struggle to justify the stock uptick".

Novo Nordisk shares overhyped? One investment bank certainly thinks they are overvalued

Ozempic maker Novo Nordisk on Thursday teased a potential successor to its blockbuster weight loss drug Wegovy, the latest in a line of next-generation obesity treatments in development as consumers flock to the powerful drugs and competitors including Eli Lilly, Pfizer and an array of startups close in to claim a share of the lucrative market.

News for Novo Nordisk Stock (NVO)